Compare Illinois Tool Works Inc. (ITW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs 10X Genomics Inc — how do they compare? Illinois Tool Works Inc. trades at $293.28 (market cap $83.88B), while 10X Genomics Inc trades at $59.38 (market cap $7.64B). The key difference: Illinois Tool Works Inc. is far larger — about 11× 10X Genomics Inc's market cap, and Illinois Tool Works Inc. pays a 2.34% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| ITW | TXG | |
|---|---|---|
Market Cap | $83.88B | $7.64B |
Sector | Industrials | Health |
52-Week High | $299.60 | $58.57 |
52-Week Low | $241.07 | $11.34 |
Enterprise Value | $92.73B | $7.17B |
Dividend Yield | 2.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $296.66, up 0.67% with a bullish technical outlook and strong support at $292. The company maintains robust profitability with 19.39% net margins and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a 7% dividend increase and $6 billion share repurchase authorization announced August 7, 2026.
While valuation metrics appear elevated (P/E 26.87, P/B 29.19), ITW's consistent earnings performance and shareholder-friendly actions support upside to the $316 consensus target. Key risks include construction sector exposure and currency headwinds, but operational strength and margin discipline provide stability.
TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.
The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
